Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics
Tóm tắt
Studies have indicated that intracameral administration of moxifloxacin (MFLX), a fourth-generation fluoroquinolone, is safe and effective. However, administration methods vary between studies, and no definite protocol exists. A prospective study clarifying the incidence of endophthalmitis and complication rates associated with each administration method would require an extremely large sample size because endophthalmitis has a low incidence rate. Therefore, we investigated appropriate intracameral MFLX administration methods by assessing intraocular concentrations following simple injection and flushing, and by measuring drug kinetics (half-life). Experiment 1: (human eyes). Irrigation (flushing) with 33.33 μg/ml MFLX (150-fold dilution) and simple injection with 0.1 ml of 500 μg/ml MFLX (10-fold dilution) were assessed after cataract surgery. Experiment 2: (rabbits: kinetics study). Flushing with 30-fold or 150-fold dilutions of MFLX was assessed. Aqueous humor samples (0.1 ml) obtained immediately after irrigation and 1, 3, and 5 h after irrigation were analyzed using high-performance liquid chromatography. Experiment 1: MFLX (500 μg/ml) administered using simple injection in humans underwent a 3.3-fold dilution (152.33 μg/ml). Total anterior chamber displacement after flushing with 33.33 μg/ml MFLX resulted in a concentration of 29.54 μg/ml (90 % displacement). Experiment 2: Concentrations at baseline were 52 % at 1 and 15 % at 3 h respectively, suggesting that the half-life of intracameral MFLX was >1 h. Considering that the half-life of MFLX was >1 h, a final concentration of 150 μg/ml results in a 2 h concentration of 38 μg/ml, which was beyond the minimum inhibitory concentration required to inhibit the growth of 90 % of bacteria (MIC90) for most resistant pathogens. We postulate that a final concentration of 150 μg/ml is considerably effective and safe. However, more resistant bacteria will evolve in the future, and the standard MIC90 may change accordingly. Therefore, even if a suitable concentration is determined, it may not necessarily remain constant. This effective concentration should be continually revised on the basis of safety and effectiveness assessments.
Tài liệu tham khảo
Ciulla TA, Starr MB, Masket S (2002) Bacterial endophthalmitis prophtlaxis for cataract surgery: an evidence-based update. Ophthalmology 109:13–24
Endophthalmitis Surgery Group, European Society of Cataract & Refractive Surgeons (2007) Prophylaxis of post-operative endophthalmitis following cataract surgery. Result of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 33:978–988
Espiritu CR, Ramon CG, Caparas VL, Bolinao JG (2007) Safety of prophylactic intracameral moxifloxacin 0.5 % ophthalmic solution in cataract patients. J Cataract Refract Surg 33:63–68
Kim SY, Park YH, Lee YC (2008) Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Exp Ophthalmol 36:367–370
Lane SS, Osher RH, Masket S, Belani S (2008) Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 34:1451–1459
O’Brien TP, Arshinoff SA, Mah FS (2007) Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 33:1790–1800
Arbisser LB (2008) Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg 34:1114–1120
Matsuura K, Suto C, Inoue Y, Saeki Y, Miyamoto T, Moti T, Ohkubo S, Tanito M (2012) Japanese survey of perioperative antibiotic prophylaxis in cataract surgery. Asia-Pac J Ophthalmol 1:283–286
Arshinoff SA, Batianelli PA (2011) Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg 37:2105–2114
Matsuura K, Suto C, Akura J, Inoue Y (2012) Bag and chamber flushing: a new method of using intracameral moxifloxacin to irrigate the anterior chamber and the area behind the intraocular lens. Graefes Arch Ophthalmol 251:83–87
Soto AM (2001) The effect of topical povidone–iodine, intraocular vancomycin, or both on aqueous human cultures at the time of cataract surgery. Am J Ophthalmol 131:293–300
Lehman OJ, Thompson JP, White LO, Keys MF, Champbell MJ (1997) Half-life of intracameral gentamicin after phacoemulsification. J Cataract Refract Surg 26:883–888
Montan PG, Wejde G, Setterquist H, Rylander M, Zetterstorm C (2002) Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 28:982–987
Kernt M, Neubauer AS, Liegl RG, Lackerbauer CA, Eibl KH, Alge CS, Ulbig MW, Kampik A (2009) Intracameral moxifloxacin: in vitro safety on human ocular cells. Cornea 28:553–561
Metzler K, Hansen GM, Hedlin P, Harding E, Drkica K, Blondeau JM (2004) Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluonoquinolones against clinical isolates of methicillin-susceptible and–resistant Staphylococcus aureus. Int J Antimicrob Agents 24:161–167
Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T (2007) Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol 55:15–19
Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW (2006) In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 124:479–483
Harper T, Miller D, Flynn HW Jr (2011) In vitro efficacy and pharmacodynamics indices for antibiotics against susceptible and resistant PA. Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg 37:2105–2114